Innovative Medicines Initiative TRISTAN Project Launches to Leverage the Potential of Imaging Techniques in Drug Safety Assessment
13 Apr 2017
Bioxydyn is proud to announce that it is co-coordinating the new 5-year IMI2 TRISTAN project. As announced by the coordinating organisation, EORTC, TRISTAN (Translational Imaging in Drug Safety Assessment) is a public-private partnership supported by the Innovative Medicines Initiative (IMI) and involves 21 organisations including academics centres, research organisations, small and medium-size enterprises (SMEs), imaging and pharmaceutical companies. The objective of the project is to validate or qualify translational imaging methods as potential imaging biomarkers. The imaging biomarker qualification will be specifically addressed in three areas with a high unmet medical need: the assessment of liver toxicity, lung toxicity and the bio-distribution of biologics. The in-kind contributions to the project of around EUR 12 million by the industrial partners are complemented by IMI-funding in a total budget of EUR 24 million. TRISTAN is led by Bayer and coordinated by the European Organisation for Research and Treatment of Cancer (EORTC).
Bioxydyn will have a crucial role in TRISTAN. In addition to our role in co-coordinating the overall project, we have co-leadership roles for two of four work packages (on imaging of drug induced liver toxicity and on imaging of drug induced interstitial lung disease). Our contribution to the programme of work will include research imaging physics expertise, imaging operational support of clinical trials and the development of software.
The research leading to these results received funding from the Innovative Medicines Initiatives 2 Joint Undertaking under grant agreement No 116106. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.